GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Adagrasib tablets (Krazati)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Krazati

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Adagrasib tablets (Krazati) - selected U.S. label sections

Product / population
KRAZATI oral tablets for the applicable adult oncology indication.
Renal measure
Cockcroft-Gault CrCl in mL/min

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Renal pharmacokinetic comments

No clinically significant pharmacokinetic differences are expected with CrCl 15 to below 90 mL/min. This statement does not establish a regimen for CrCl below 15 or dialysis.

Renal adverse-event context

Renal impairment, including acute kidney injury and increased creatinine, is reported among adverse reactions. Lack of a baseline PK effect is not evidence that renal toxicity cannot occur.

Source revision: Revision not captured; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b8bf078-34c2-4f45-9012-38a8ac082b01

Scope: Local label summary; independent clinical review pending. Not a two-source validated protocol. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Adagrasib tablets (Krazati) - selected U.S. label sections

KRAZATI oral tablets for the applicable adult oncology indication.

Renal method: Cockcroft-Gault CrCl in mL/min
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - KRAZATI

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Oral adagrasib; selected renal PK expectation, not all indication/interaction instructions.

Renal method: Cockcroft-Gault CrCl 15 to <90 mL/min.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeAdagrasib tablets (Krazati) - selected U.S. label sectionsGlobalRPh RX List - KRAZATI
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b8bf078-34c2-4f45-9012-38a8ac082b01

Product and population scope

KRAZATI oral tablets for the applicable adult oncology indication.

RDM32-adagrasib-krazati-scope · Source section: Editorial scope for the selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Adagrasib tablets (Krazati) - selected U.S. label sections

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · KRAZATI oral tablets for the applicable adult oncology indication.

Renal method: Cockcroft-Gault CrCl in mL/min
Source date: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Renal pharmacokinetic comments

No clinically significant pharmacokinetic differences are expected with CrCl 15 to below 90 mL/min. This statement does not establish a regimen for CrCl below 15 or dialysis.

RDM32-adagrasib-krazati-1 · Source locator: 12.3

Renal adverse-event context

Renal impairment, including acute kidney injury and increased creatinine, is reported among adverse reactions. Lack of a baseline PK effect is not evidence that renal toxicity cannot occur.

RDM32-adagrasib-krazati-2 · Source locator: 6.1

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b8bf078-34c2-4f45-9012-38a8ac082b01
Retrieved
2026-09-05
DailyMed Set ID
0b8bf078-34c2-4f45-9012-38a8ac082b01
Renal-function method
Cockcroft-Gault CrCl in mL/min
Source date/version
Revision not captured; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256
0c3b9aae946aa666a2136f03816e45d7a019caad55d00f7db84d5c9223863deb
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - KRAZATI

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Oral adagrasib; selected renal PK expectation, not all indication/interaction instructions.

Renal method: Cockcroft-Gault CrCl 15 to <90 mL/min.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The source expects no clinically significant pharmacokinetic difference across mild-to-severe impairment, CrCl 15 to <90. Do not convert that expectation into a tested dialysis regimen or extend it below the stated range. Treatment-emergent kidney injury is a separate safety question.

RDM42-rxlist-adagrasib-krazati-e521d4d6f5-C1 · Source locator: Clinical Pharmacology / Specific Populations

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/krazati-drug/
Retrieved
2026-09-07
Renal-function method
Cockcroft-Gault CrCl 15 to <90 mL/min.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
9b421b64078579c2d4f0e98a47d7eb55659ca4fec77e8a83e555b9fc0c71b546

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b8bf078-34c2-4f45-9012-38a8ac082b01
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
df3c903a893d29802a2e33e7d0cb2fb53081a7b071b839fba123d291ae4e896d
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report